Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Divestments (2020 - 2021)

Myriad Genetics (MYGN) has disclosed Divestments for 2 consecutive years, with $379.1 million as the latest value for Q3 2021.

  • On a quarterly basis, Divestments rose 1679.81% to $379.1 million in Q3 2021 year-over-year; TTM through Dec 2024 was $379.1 million, a 0.0% change, with the full-year FY2024 number at $8.8 million, changed N/A from a year prior.
  • Divestments was $379.1 million for Q3 2021 at Myriad Genetics, up from $21.3 million in the prior quarter.
  • In the past five years, Divestments ranged from a high of $379.1 million in Q3 2021 to a low of -$21.3 million in Q2 2020.